Cue Biopharma (NASDAQ:CUE) Stock: Insider Michael Vincent Meluzio Sells 1,144 Shares

Posted by Geri Gentry on Oct 16th, 2026

Cue Biopharma, Inc. (NASDAQ:CUE – Get Free Report) VP Michael Vincent Meluzio sold 1,144 shares of the stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $28.05, for a total transaction of $32,089.20. Following the sale, the vice president directly owned 47,817 shares in the company, valued at approximately $1,341,266.85. The trade was a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Vincent Meluzio also recently made the following trade(s):

On Thursday, August 13th, Michael Vincent Meluzio sold 5,628 shares of Cue Biopharma stock. The shares were sold at an average price of $30.09, for a total value of $169,346.52.

Cue Biopharma Stock Performance

NASDAQ:CUE opened at $18.67 on Friday. Cue Biopharma, Inc. has a 52 week low of $4.97 and a 52 week high of $45.50. The stock’s 50-day moving average price is $27.57 and its 200-day moving average price is $70.86.

Cue Biopharma (NASDAQ:CUE – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($24.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The business had revenue of $7.88 million during the quarter, compared to analyst estimates of $3.00 million. Cue Biopharma had a negative return on equity of 620.06% and a negative net margin of 435.83%. As a group, equities research analysts anticipate that Cue Biopharma, Inc. will post -21.79 EPS for the current fiscal year.

Institutional Trading of Cue Biopharma

Institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. purchased a new position in Cue Biopharma in the 2nd quarter valued at about $83,000. Bank of America Corp DE acquired a new stake in Cue Biopharma in the 2nd quarter worth about $219,000. Seven Fleet Capital Management LP purchased a new stake in Cue Biopharma during the 2nd quarter worth approximately $338,000. Persistent Asset Partners Ltd purchased a new stake in Cue Biopharma during the 2nd quarter worth approximately $389,000. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new stake in Cue Biopharma during the 2nd quarter worth approximately $722,000. Institutional investors and hedge funds own 35.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Weiss Ratings cut Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. Wall Street Zen downgraded Cue Biopharma from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 26th. Zacks Research upgraded Cue Biopharma to a “hold” rating in a research report on Monday, September 21st. Finally, B. Riley Financial started coverage on Cue Biopharma in a research report on Friday, September 18th. They set a “buy” rating and a $83.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $83.00.

Check Out Our Latest Research Report on Cue Biopharma

Cue Biopharma Company Profile

(Get Free Report)

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.

Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens.